Table 1.
Patients characteristics.
| Patient | Age (years) | PSA (ng/ml) | TNM | Gleason score | PCa (% of prostate tissue) |
|---|---|---|---|---|---|
| 1 | 52 | 51.1 | pT3b pN1 cM0 | 5+4 (9) | 43% |
| 2 | 51 | 17.4 | pT3a pN0 cM0 | 4+3 (7b) | 8% |
| 3 | 59 | 9.2 | pT2c pN0 cM0 | 4+3 (7b) | 5% |
| 4 | 74 | 15.0 | pT2c pN0 cM0 | 3+4 (7a) | 3% |
| 5 | 76 | 20.7 | pT2c pN0 cM0 | 4+3 (7b) | 15% |
| 6 | 59 | 15.8 | pT3b pN1 cM0 | 4+5 (9) | 21% |
| 7 | 73 | 40.0 | pT3a pN1 cM0 | 4+5 (9) | 21% |
| 8 | 53 | 16.3 | pT3a pN0 cM0 | 4+4 (8) | 8% |
| 9 | 72 | 28.9 | pT3b pN1 cM0 | 4+4 (8) | 15% |
| 10 | 67 | 218.0 | pT3b pN0 cM0 | 4+4 (8) | 55% |
| 11 | 67 | 6.1 | pT3a pN0 cM0 | 3+4 (7a) | 15% |
| 12 | 48 | 23.0 | pT3b pN1 cM0 | 4+3 (7b) | 42% |
| 13 | 66 | 17.2 | pT3 pN0 cM0 | 4+3 (7b) | 16% |
| 14 | 70 | 61.0 | pT3b pN0 cM0 | 4+3 (7b) | 4% |
| 15 | 69 | 103.0 | pT3a pN0 cM0 | 4+5 (9) | 7% |
| 16 | 76 | 5.0 | pT2c pN0 cM0 | 4+3 (7b) | 9% |
| 17 | 75 | 17.8 | pT2c pN0 cM0 | 3+4 (7a) | 6% |
| 18 | 53 | 72.0 | pT3b pN1 cM0 | 5+4 (9) | 28% |
| 19 | 64 | 19.5 | pT3a pN0 cM0 | 4+4 (8) | 7% |
| 20 | 72 | 24.8 | pT2a cM0 cM0 | 4+4 (8) | 1% |
| 21 | 74 | 13.9 | pT3a pN0 cM0 | 4+3 (7b) | 7% |
| 22 | 66 | 17.5 | pT3b pN1 cM1 | 4+5 (9) | 43% |
| Min | 48 | 5,0 | 3+4 (7a) | 1% | |
| Max | 76 | 218 | 5+4 (9) | 55% | |
| Mean | 65 | 37.0 | 17% |
PSA and cM were defined preoperatively; pT, pN and Gleason score were assessed postoperatively after histopathological diagnostic of the resected prostate and lymph nodes. The sixth column informs about the PCa´s percentage of the prostate tissue with PCa defined using GTV-Histo.